N-(1-Isopropyl-2-methyl-propyl)-hydroxylamine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(1-Isopropyl-2-methyl-propyl)-hydroxylamine
• 英文别名: N-(2,4-dimethylpentan-3-yl)hydroxylamine
• 化学式: C₇H₁₇NO
• 分子量: 131.218
• InChiKey: KUKIXNJMJLKCHQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (S_a)-2'-methoxy-1,1'-binaphthyl-2-carboxylic acid chloride 、 N-(1-Isopropyl-2-methyl-propyl)-hydroxylamine 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 生成 2'-Methoxy-[1,1']binaphthalenyl-2-carboxylic acid hydroxy-(1-isopropyl-2-methyl-propyl)-amide
  参考文献：
  名称：

  钒催化不对称环氧化反应中作为配体的光学活性异羟肟酸的设计

  摘要：

  在钒催化的不对称环氧化反应中，制备了带有 1,1'-联萘基团的新型旋光异羟肟酸作为配体。这些异羟肟酸的特征是空间位阻配体。在-20 °C 的甲苯中，使用 VO(Oi-Pr)3 (5 mol%) 和少量过量的配体 (7.5 mol%) 与三苯甲基氢过氧化物 (TrOOH) 可以建立具有良好选择性和反应性的不对称环氧化反应. 二取代的烯丙醇比单取代或三取代的烯丙醇环氧化得更快，并且以良好到高的对映选择性 (48-94%ee) 获得。讨论了基于 1e 的 X 射线晶体结构的过渡态。

  DOI：

  10.1246/bcsj.73.1653

文献信息

• [EN] HIV PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE LA PROTÉASE DU VIH
  申请人：MERCK SHARP & DOHME

  公开号：WO2014043019A1

  公开（公告）日：2014-03-20

  The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

  公式I所涵盖的化合物包括HIV蛋白酶抑制剂和其他可在体内代谢为HIV蛋白酶抑制剂的化合物。这些化合物及其药学上可接受的盐对于预防或治疗HIV感染以及预防、治疗或延迟艾滋病的发作非常有用。这些化合物及其盐可以作为药物组合物的成分，可选择与其他抗病毒药物、免疫调节剂、抗生素或疫苗组合使用。
• Nanocomplexes for delivery of saporin
  申请人：Trustees of Tufts College

  公开号：US10792328B2

  公开（公告）日：2020-10-06

  A nanocomplex, of particle size 50 nm to 1000 nm, containing saporin and a lipid-like compound, in which saporin binds to the lipid-like compound via non-covalent interaction or covalent bonding. The lipid-like compound has a hydrophilic moiety, a hydrophobic moiety, and a linker joining the hydrophilic moiety and the hydrophobic moiety. The hydrophilic moiety is optionally charged and the hydrophobic moiety has 8 to 24 carbon atoms. Also disclosed is a pharmaceutical composition containing such a nanocomplex and a pharmaceutically acceptable carrier. The nanocomplex is useful in treating diseases, such as cancer.

  一种粒径为 50 纳米至 1000 纳米的纳米复合物，含有沙波林和类脂化合物，其中沙波林通过非共价作用或共价键与类脂化合物结合。类脂化合物具有亲水性分子、疏水性分子以及连接亲水性分子和疏水性分子的连接体。亲水分子可选择带电，疏水分子有 8 至 24 个碳原子。还公开了一种药物组合物，其中含有这种纳米复合物和药学上可接受的载体。该纳米复合物可用于治疗癌症等疾病。
• HIV PROTEASE INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2895482B1

  公开（公告）日：2016-10-19
• DISULFIDE COMPOUNDS FOR DELIVERY OF PHARMACEUTICAL AGENTS
  申请人：XU Qiaobing

  公开号：US20160009643A1

  公开（公告）日：2016-01-14

  A compound of formula the following formula: (I). In this formula, moieties A, B, X, R 1 , R 2 , and R 3 are defined herein. Also disclosed are a nanocomplex that is formed of such a compound and a pharmaceutical agent, and a nanocomplex that is formed of a protein and a bioreducible compound.
• NANOCOMPLEXES FOR DELIVERY OF SAPORIN
  申请人：TUFTS UNIVERSITY

  公开号：US20160082126A1

  公开（公告）日：2016-03-24

  A nanocomplex, of particle size 50 nm to 1000 nm, containing saporin and a lipid-like compound, in which saporin binds to the lipid-like compound via non-covalent interaction or covalent bonding. The lipid-like compound has a hydrophilic moiety, a hydrophobic moiety, and a linker joining the hydrophilic moiety and the hydrophobic moiety. The hydrophilic moiety is optionally charged and the hydrophobic moiety has 8 to 24 carbon atoms. Also disclosed is a pharmaceutical composition containing such a nanocomplex and a pharmaceutically acceptable carrier. The nanocomplex is useful in treating diseases, such as cancer.